(secondQuint)SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma.

 OBJECTIVES: I.

 Determine the response rate and response duration of patients with refractory or relapsed multiple myeloma treated with SU5416.

 II.

 Determine the toxicity of SU5416 in this patient population.

 OUTLINE: This is a multicenter study.

 Patients receive SU5416 IV over 1 hour twice weekly.

 Treatment continues in the absence of unacceptable toxicity or disease progression.

 Patients are followed for survival.

 PROJECTED ACCRUAL: A total of 20-38 patients will be accrued for this study within 2 years.

.

 SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma@highlight

RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells.

 PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma.

